Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2017-03-21
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies different combinations of bevacizumab, temsirolimus,
and sorafenib tosylate to see how well they work compared with bevacizumab alone in treating
patients with kidney cancer that has spread to other places in the body. Monoclonal
antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and
spread. Bevacizumab and sorafenib tosylate may stop the growth of tumor cells by blocking
blood flow to the tumor. Temsirolimus and sorafenib tosylate may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving different combinations
of bevacizumab, sorafenib tosylate, and temsirolimus may be more effective than bevacizumab
alone in treating metastatic kidney cancer.